AbbVie reports 90% response in lung cancer study

• AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose.
• The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose.
• AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer.

AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy.

At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company.

AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose.

The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer.

AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients.

The company’s conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer.

The updates form part of AbbVie’s clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings.